Home » Regions » Global News » ASLAN, Sinica’s Genomic Research Centre partner

ASLAN, Sinica’s Genomic Research Centre partner

Thursday, August 17, 2017

ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumor types, announced the signing of a research collaboration agreement with Academia Sinica’s Genomic Research Centre, one of Taiwan’s eminent research institutions. 

In recent studies with varlitinib, major responses were seen in a number of patients with advanced disease and with difficult to treat tumors, such as biliary tract cancer. The collaboration with Academia Sinica will build on the research ASLAN has been conducting to understand the genetic mutations responsible for varlitinib sensitivity. The research collaboration will also evaluate the effectiveness of combining varlitinib and ASLAN003 in animal models for gastric, colorectal and lung cancers, in addition to other tumor types. 

Dr Michael Hsiao, a Research Fellow in the Genomics Research Centre, and Dr Ming-Huang Chen, an attending physician from Taipei Veterans General Hospital, will lead the research collaboration. 

Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed across multiple indications including biliary tract, gastric, metastatic breast and metastatic colorectal cancers. ASLAN003 is a highly potent, best-in-class, small molecule inhibitor of DiHydroOrotate DeHydrogenase (DHODH) enzyme, and is currently being developed in acute myeloid leukaemia. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!